Showing 112 of 112on this page. Filters & sort apply to loaded results; URL updates for sharing.112 of 112 on this page
Axsome Therapeutics logo in transparent PNG and vectorized SVG formats
Axsome Therapeutics Logo, HD Png Download , Transparent Png Image - PNGitem
Logo de Axsome Therapeutics aux formats PNG transparent et SVG vectorisé
PNG Images, Transparent Image Download , Page 20336 - PNGitem
Positive Phase III data in narcolepsy from Axsome | The Pharmaletter
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor ...
HCP Registration - Axsome Therapeutics
Axsome Therapeutics, Inc.
Axsome advances solriamfetol into Phase 3 trial in adolescent ADHD as ...
Axsome Therapeutics - Samedan
Axsome Therapeutics - LifeScienceHistory.com
Axsome Therapeutics announces selling of common stock in a public ...
Axsome Q4 Earnings: Revenue Soars 66% to $119M, Auvelity Sales Jump 89% ...
Axsome Therapeutics (AXSM) Buy, Sell or Hold — Stockchase
Why Did Axsome Therapeutics Stock Hit Another Record High Today? | The ...
HighTower Advisors LLC Grows Stock Position in Axsome Therapeutics, Inc ...
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ...
Exhibitor - Axsome Therapeutics | UW–Madison ICEP
Axsome Speaker Bureau
AXS-12 - Axsome Therapeutics
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression ...
Axsome (AXSM) sales jump 66% to $638M; eyes April FDA date | Grafa
Axsome Stock Adds Onto Record-High Sprint With In-Line First-Quarter ...
Axsome Therapeutics Unveils Mixed Results In ADHD Treatment. Axsome ...
This Photo Illustration Axsome Therapeutics Logo Editorial Stock Photo ...
In this photo illustration, the Axsome Therapeutics logo is displayed ...
Axsome Therapeutics: Neuroscience Innovator Gains Momentum - Stocks Today
Axsome Therapeutics營收表現亮眼,股價或有潛力
Is Axsome Therapeutics Positioned to Lead the Neuroscience Revolution ...
Neuroscience Education Institute (NEI) 2025 – Axsome Medical Affairs
Axsome Therapeutics Emerges as a High-Growth Contender in Neurological ...
Axsome Therapeutics (AXSM) - P/S ratio
Axsome Therapeutics Reaches $7.75 Million Settlement in Investor ...
Axsome Therapeutics: Navigating a Pivotal Phase with High Expectations ...
Axsome Therapeutics (AXSM) Q3 2026 Earnings Results & Call Transcript
Axsome Therapeutics Aktie: Analystin bekräftigt Kaufempfehlung trotz ...
Axsome Therapeutics Positions for Major Commercial Expansion - Stocks Today
Axsome Therapeutics to Participate in Upcoming Investor Conferences ...
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates ...
Axsome Therapeutics Surpasses $1 Billion Annual Run Rate with 52% Year ...
Axsome Therapeutics Narrows Q3 2026 Loss, Beating Estimates - Alphastreet
Axsome Sinks 10% Despite Q3 Revenue Beat “Surpassing a One-Billion ...
Axsome Aktie: UBS stutzt das Kursziel auf 239 Dollar
Axsome Therapeutics Releases Q3 2026 Financial Results - Alphastreet
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome (AXSM) Q3 2026 Earnings Call Transcript
Axsome Therapeutics Leads Market in Turnover as $0.24 Billion Volume ...
Axsome Q3 2026: Loss Narrows Sharply as Revenue Tops $259M | 24/7 Wall St.
Why Axsome Therapeutics shares are falling today | Quiver Quantitative
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp ...
Axsome Q3 2026 slides: 52% revenue growth, stock falls on concerns By ...
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Axsome Therapeutics-Aktie mit neuem 6-Monats-Tief - boerse.de
Axsome Therapeutics Shares Hit 52-Week Low as Much as… - SquawkNews
Axsome Therapeutics (AXSM) kerncijfers 2025 — De Belegger
Axsome Therapeutics (AXSM) Q3 2026 Earnings Date, Time & Estimates
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on ...
Axsome Therapeutics, Inc (AXSM) Q3 2026 Earnings Call | StockNow
Axsome Therapeutics (AXSM) aandeel koers — De Belegger
Axsome Therapeutics Inc (AXSM) Misses Revenue Estimates in Q2 20
AXSOME THERAPEUTICS, INC. : BAIRD CUTS TARGET PRICE TO $220 FROM $246
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call - NewsBreak
Axsome Therapeutics (AXSM) Beats Q3 Earnings Estimates by $0.39 ...
AACSM – (AACSM) Cardiovascular Sleep Medicine Resources
Veeva Compass Patient | Longitudinal Patient Data
2025 Sponsors | Practical Updates in Primary Care
2026 Spring Meeting - Nebraska Neurological Society
Mastering Migraine Therapies | American Headache Society
Axsomeがアルツハイマー病の研究からのデータを公表、アナリストは混合した試験結果にも希望を見出す - Benzinga Japan
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug ...
About Us | The Adpharm
Axsome'un DEHB ilacı olumlu sonuç verdi - Midas
Reboxetine - Drug Targets, Indications, Patents - Synapse
Headache in the City | Migraine Awareness Campaign | New York City
With three approved products and filings for more over the near term ...
Research — Tricoastal Narcolepsy and Sleep Disorders Center
Insider Sales Cast Shadow Over Axsome's Strong Fundamentals - Stocks Today
Axsome: Q3 Earnings Snapshot | 12news.com
Axsome’s Revenue Surges, But Losses Persist Ahead of Q3 | AInvest
Axsome: Q3 Earnings Snapshot | wnep.com
Axsome: Revenue Is Up 52% While the Stock Is Down 44% — Growth Was ...
Axsome: Q3 Earnings Snapshot | king5.com
Axsome: 3 Key Takeaways for Long-Term Investors - AOL
Axsome's Alzheimer's Agitation Launch Faces First Full-Quarter Test As ...
2026 Walk to End Alzheimer's - Anderson, SC | Walk to End Alzheimer's
Axsome: Q3 Earnings Snapshot – WTOP News